These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35373680)

  • 1. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.
    Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K
    Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
    Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
    BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
    Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
    Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
    Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
    Catanese L; Link K; Rupprecht H
    BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
    Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
    Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Attucci I; Pilerci S; Messeri M; Pengue L; Tomasino G; Caroti L; Vannucchi AM; Antonioli E
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e2163. PubMed ID: 39390755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
    Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
    Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
    Fang W; Sun W; Fang W; Zhao S; Wang C
    Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
    Kozlowski P; Kameran Behnam K; Uggla B; Åström M
    Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
    Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G
    Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient.
    Jeyaraman P; Borah P; Singh A; Chhabra GD; Khullar D; Dayal N; Naithani R
    Blood Cells Mol Dis; 2020 Mar; 81():102400. PubMed ID: 31887694
    [No Abstract]   [Full Text] [Related]  

  • 15. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA.
    Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D
    Blood Cancer J; 2023 Jul; 13(1):113. PubMed ID: 37495597
    [No Abstract]   [Full Text] [Related]  

  • 16. Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review.
    Meseha M; Qu D; Lykon J; Coffey D
    Ann Hematol; 2024 Oct; 103(10):4313-4317. PubMed ID: 39191958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib-induced thrombotic microangiopathy. A case report.
    Scheggi V; Merilli I; Cesaroni E; Alterini B
    J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombotic microangiopathy with gastrointestinal hemorrhage during carfilzomib therapy for multiple myeloma].
    Matsumoto S; Takahashi H; Hamada T; Miura K; Nakagwa M; Kurihara K; Endo T; Koike T; Iizuka K; Iriyama N; Nakayama T; Hatta Y; Nakamura H
    Rinsho Ketsueki; 2023; 64(4):255-259. PubMed ID: 37121768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
    Fotiou D; Roussou M; Gakiopoulou C; Psimenou E; Gavriatopoulou M; Migkou M; Kanellias N; Dialoupi I; Eleutherakis-Papaiakovou E; Giannouli S; Delavinia C; Efstathiou K; Kontogiannis S; Terpos E; Dimopoulos MA; Kastritis E
    Blood Cancer J; 2020 Nov; 10(11):109. PubMed ID: 33149167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
    Fujimori C; Hagino T; Osanai S; Sano S; Saga R; Hidai H; Kurimoto M; Murai Y; Akiyama H; Motomura S
    Rinsho Ketsueki; 2022; 63(12):1626-1632. PubMed ID: 36653134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.